Helicobacter

Helicobacter Pylori Testing Global Market Report 2022: Danger of Peptic Ulcers and Gastric Cancer Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022

The report provides an overview of the global Helicobacter pylori testing market and analyzes market trends.

Key Points: 
  • The report provides an overview of the global Helicobacter pylori testing market and analyzes market trends.
  • Increasing cases of gastric ulcers, the rising prevalence of H. pylori infection in the geriatric population, and growing demand for point-of-care testing devices are the key factors driving the growth of the Helicobacter pylori testing market.
  • In this report, the global Helicobacter pylori testing market is segmented based on test type, end user and geography.
  • By geography, the Helicobacter pylori testing market is segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 2, 2022

On May 4, 2022, Phathom announced the signing of a revenue interest financing agreement for up to $260 million of non-dilutive financing.

Key Points: 
  • On May 4, 2022, Phathom announced the signing of a revenue interest financing agreement for up to $260 million of non-dilutive financing.
  • Second Quarter 2022 Financial Results:
    Net loss for the second quarter ended June 30, 2022 was $50.9 million, compared to $36.6 million for second quarter 2021.
  • Second quarter 2022 net loss included a non-cash charge related to stock-based compensation of $5.9 million compared to the second quarter of 2021 non-cash charge related to stock-based compensation of $4.2 million.
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

How high-fat diets allow cancer cells to go unnoticed

Retrieved on: 
Tuesday, September 28, 2021

Certain immune cells look for tags that distinguish between normal and abnormal cells.

Key Points: 
  • Certain immune cells look for tags that distinguish between normal and abnormal cells.
  • Beyaz and his colleagues found that when mice ate diets high in fat, MHC-II levels were suppressed in intestinal cells.
  • Several bacteria, including ones called Helicobacter, increase MHC-II, which may help immune cells locate abnormal cells.
  • Cancer cells use many tricks to avoid being recognized as abnormal by the immune system, but Beyaz hopes he's found several ways to outwit them.

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.

Retrieved on: 
Friday, July 23, 2021

With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.

Key Points: 
  • With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.
  • We look forward to supporting Otsukas customers with the gastrointestinal expertise and world class customer service Meridian is known for.
  • Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
  • Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products.

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021

Retrieved on: 
Friday, May 21, 2021

We then used the new classifications to assess the efficacy of rifamycin, reconfirming highly statistically significant efficacy across both newly reclassified moderate and severe patient groups.

Key Points: 
  • We then used the new classifications to assess the efficacy of rifamycin, reconfirming highly statistically significant efficacy across both newly reclassified moderate and severe patient groups.
  • "\n"Outcomes-focused clinical tools to assess the prognosis in TD have been lacking, and the development of this new Travelers\' Diarrhea severity classification tool provides prognostic information that may help guide clinical practice," said June Almenoff, M.D., Ph.D., FACP, RedHill\'s Chief Medical Officer.
  • RedHill promotes the gastrointestinal drugs, Movantik for opioid-induced constipation in adults[vii], Taliciafor the treatment of Helicobacter pylori (H. pylori) infection in adults[viii], and Aemcolo for the treatment of travelers\' diarrhea in adults[ix].
  • All forward-looking statements included in this press release are made only as of the date of this press release.

RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021

Retrieved on: 
Thursday, May 20, 2021

RedHill promotes the gastrointestinal drugs, Movantik for opioid-induced constipation in adults[1], Taliciafor the treatment of Helicobacter pylori (H. pylori) infection in adults[2], and Aemcolo for the treatment of travelers\' diarrhea in adults[3].

Key Points: 
  • RedHill promotes the gastrointestinal drugs, Movantik for opioid-induced constipation in adults[1], Taliciafor the treatment of Helicobacter pylori (H. pylori) infection in adults[2], and Aemcolo for the treatment of travelers\' diarrhea in adults[3].
  • More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio .\nThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.
  • All forward-looking statements included in this press release are made only as of the date of this press release.

Global Helicobacter Pylori Tests (In Vitro Diagnostics) Market Analysis and Forecast Report 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021

b'The "Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com\'s offering.\nHelicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.\nThe model discusses in detail the impact of COVID-19 on Helicobacter Pylori Tests market for the year 2020 and beyond.

Key Points: 
  • b'The "Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com\'s offering.\nHelicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.\nThe model discusses in detail the impact of COVID-19 on Helicobacter Pylori Tests market for the year 2020 and beyond.
  • It gets transmitted from mother-to-child in developed countries, but horizontal transmission is not observed in developed countries due to better sanitary conditions.\nThe prevalence is lower in developed nations with a prevalence rate of 15.5% when compared to the developing countries having a prevalence rate of 93.6%.
  • The main causes for the high prevalence of infection are poverty enhanced level of transmission due to malnutrition, poor hygiene and unaffordable heath care indicating low socioeconomic status in regions like Asia, South America and Africa.
  • Helicobacter Pylori Tests is segmented into Helicobacter pylori Breath Test, Helicobacter pylori Feces Test, Helicobacter pylori IHC Test, Helicobacter pylori Serology EIA Test, Helicobacter Pylori Point of Care (POC) Tests and Helicobacter Pylori Other Tests.\nCMO executives who must have deep understanding of the Helicobacter Pylori Tests market place to make strategic planning and investment decisions.\nSourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.\nPrivate equity investors that need a deeper understanding of the market to identify and value potential investment targets.\nUnderstand the impact of COVID-19 on Helicobacter Pylori Tests market.\nDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.\nDevelop business strategies by understanding the trends shaping and driving Helicobacter Pylori Tests market.\nDrive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Helicobacter Pylori Tests market in the future.\nFormulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.\nIdentify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.\nTrack device sales in the global and country-specific Helicobacter Pylori Tests market from 2015-2030.\nOrganize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.\n'

Helicobacter Pylori Diagnostics Market to Grow Over USD 210 Million During 2020-2024 | Forecasting Strategy to Undergo a Paradigm Shift From Crisis to New Normal During COVID-19 Pandemic | Technavio

Retrieved on: 
Wednesday, November 25, 2020

The helicobacter pylori diagnostics market is poised to grow by USD 209.59 million during 2020-2024, progressing at a CAGR of over 8% during the forecast period.

Key Points: 
  • The helicobacter pylori diagnostics market is poised to grow by USD 209.59 million during 2020-2024, progressing at a CAGR of over 8% during the forecast period.
  • This is increasing the availability of rapid tests for the diagnosis of helicobacter pylori, which is influencing the market growth.
  • View the full release here: https://www.businesswire.com/news/home/20201124005749/en/
    Technavio has announced its latest market research report titled Global Helicobacter Pylori Diagnostics Market 2020-2024 (Graphic: Business Wire).
  • The report on the helicobacter pylori diagnostics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

RedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual Conferences

Retrieved on: 
Tuesday, October 6, 2020

RedHill Biopharma Ltd. (Nasdaq: RDHL ) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases.

Key Points: 
  • RedHill Biopharma Ltd. (Nasdaq: RDHL ) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases.
  • RedHill promotes the gastrointestinal drugs, Movantik for opioid-induced constipation in adults1, Talicia for the treatment of Helicobacter pylori (H. pylori) infection in adults2, and Aemcolo for the treatment of travelers diarrhea in adults3.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • All forward-looking statements included in this press release are made only as of the date of this press release.

Recce Pharmaceuticals and Murdoch Children’s Research Institute to Evaluate RECCE® 435 Against Helicobacter pylori Stomach Bacteria

Retrieved on: 
Wednesday, September 30, 2020

Murdoch Childrens Research Institute to evaluate the in-vivo antimicrobial activity of RECCE 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies program

Key Points: 
  • Murdoch Childrens Research Institute to evaluate the in-vivo antimicrobial activity of RECCE 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies program
    SYDNEY, Australia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing New Classes of Synthetic Anti-Infectives, today announced it has entered into an agreement with the Murdoch Childrens Research Institute (MCRI) to conduct preclinical studies assessing the potential of RECCE 435 (R435) for the treatment of Helicobacter pylori (H. pylori) infections.
  • Antibiotic-resistant forms of H. pylori are on the rise, stated Recce Pharmaceuticals Non-Executive Chairman, Dr. John Prendergast.
  • The research program will be carried out by the Mucosal Immunology Group at the MCRI, Royal Childrens Hospital.
  • The MCRI is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact.2
    Researchers will evaluate the antimicrobial activity of RECCE 435 against H. pylori across a range of internationally recognized in-vitro and in-vivo study models.